New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease
| Autor: | Sergey Avdeev, N V Trushenko |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2019 |
| Předmět: |
History
medicine.medical_specialty Endocrinology Diabetes and Metabolism Pulmonary disease lcsh:Medicine Muscarinic Antagonists chronic obstructive pulmonary disease Pulmonary Disease Chronic Obstructive aclidinium/formoterol combination Formoterol Fumarate Administration Inhalation medicine Humans Clinical efficacy Intensive care medicine Adrenergic beta-2 Receptor Agonists Lung COPD business.industry dual bronchodilation therapy lcsh:R Dosing regimen General Medicine medicine.disease Bronchodilator Agents respiratory tract diseases Safety profile Drug Combinations Dual bronchodilation Treatment Outcome Formoterol Delivery system Family Practice business medicine.drug Tropanes |
| Zdroj: | Терапевтический архив, Vol 91, Iss 3, Pp 76-85 (2019) |
| ISSN: | 2309-5342 0040-3660 |
| Popis: | Currently, combinations of long-acting beta2-agonists and long-acting anticholinergics are considered as the basic therapy for majority of patients with chronic obstructive pulmonary disease (COPD). These combinations have different pharmacological characteristics and delivery devices that provides different clinical effects and new opportunities for personalized treatment of COPD. Aclidinium/formoterol fixed combination differs from other dual bronchodilators by twice-daily dosing regimen, good safety profile and a specific delivery system. Recent information on clinical efficacy and safety of aclidinium/formoterol combination in COPD patients is given in this article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|